Natco Pharma files ANDA for generic Tykerb

23 Jun 2011 Evaluate

Natco Pharma has filed an Abbreviated New Drug Application (ANDA) for generic version of Lapatimb Ditosylate tablets in 250mg strength. The company is first to file applicant for this product, possibly leading to 180 days marketing exclusivity.

The innovator product (Tykerb tablets by Glaxo), used for the treatment of breast cancer, clocked revenues of $114 million in the USA last year. Natco has partnered with Lupin for marketing of the said product.

Following this, Natco has five IV challenges on hand, with four first to file opportunities.

Natco Pharma was promoted by V C Nannapaneni in the year 1981 as a private company to be in the business of research, developing, manufacturing and marketing of pharmaceutical substances and finished dosage forms for Indian and International markets.

Natco Pharma Share Price

933.60 -15.25 (-1.61%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×